The purpose of this study is to compare the short-term (8 week) mean 24-hour IOP control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma...
Date First Received: May 26, 2006
Last Updated: September 22, 2008
Verified by: Aristotle University Of Thessaloniki, September 2008
Clinical Trial Phase: Phase 3 | Start Date: March 2006
Overall Status: Completed
Estimated Enrollment: 32
Brief Summary
Condition Keyword(s):
The purpose of this study is to compare the short-term (8 week) mean 24-hour IOP control and safety of TravTim fixed combination given once in the evening with placebo once in the morning versus TravTim given once in the morning with placebo once in the evening in patients with open-angle glaucoma.
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment
Intervention(s) in this Clinical Trial
- Drug: travoprost/timolol fixed combination
- Drug: placebo (artificial tears)
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- POAG
- Exfoliation syndrome
Exclusion Criteria:
- Advanced glaucoma
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 29 Years
Maximum Age for this Clinical Trial: 80 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Sponsor Information
Lead Sponsor: Aristotle University Of Thessaloniki
Overall Clinical Trial Officials and Contacts
AGP Konstas, MD, PhD Principal Investigator Glaucoma Unit, A University Dept of Ophthalmology, AHEPA Hospital
Additional Information
Information obtained from ClinicalTrials.gov on July 02, 2009
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00331240
Study ID Number: A1457
ClinicalTrials.gov Identifier: NCT00331240
Health Authority: Greece: National Organization of Medicines
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
